MBI spurs review of Nycomed patent
The U.S. Patent Office has granted a petition from Molecular Biosystems of San Diego asking for a review of an ultrasound contrast agent patent issued to Norwegian contrast developer Nycomed. MBI was granted a similar petition in July relating to
The U.S. Patent Office has granted a petition from Molecular Biosystems of San Diego asking for a review of an ultrasound contrast agent patent issued to Norwegian contrast developer Nycomed. MBI was granted a similar petition in July relating to ultrasound contrast patents received by Sonus Pharmaceutical (SCAN 8/6/97).
MBI said it filed the petition in response to Nycomed's assertion that MBI's Optison contrast agent infringes on one of its patents, U.S. patent no. 5,529,766. Nycomed filed patent infringement claims on Sept. 2 against MBI and Mallinckrodt, and in the same action sought to have its patents take priority over those of Sonus (SCAN 9/17/97).
MBI claims that it brought to the patent office's attention certain prior art references that were not included in Nycomed's patent application. MBI believes that the use of perfluorocarbon gases for ultrasound imaging is not patentable because of the prior art references.
MBI and its marketing partner Mallinckrodt also filed litigation in July in U.S. District Court for the District of Columbia, seeking to have the patents of Nycomed, Bracco, ImaRx Pharmaceutical and Du Pont Merck, and Sonus declared invalid.
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Study: Monitoring of Prostate MRI Exams Could Lead to 75 Percent Reduction of Gadolinium Contrast
March 17th 2025While DCE MRI was deemed helpful in over 67 percent of cases in which it was used, researchers found that monitored prostate MRI exams, which facilitated a 75 percent reduction of DCE MRI sequences, had comparable sensitivity for prostate cancer as non-monitored exams.
